





## BeOne Medicines U.S. Biologics Manufacturing and Clinical R&D Facility


Princeton West Innovation Campus,  
Hopewell, New Jersey, USA

State-of-the-art, clinical and commercial-stage biologics manufacturing facility and clinical R&D center spans 42 acres, represents an \$800 million capital investment, and complements BeOne's existing capabilities around the world.

### Diversified Modalities

-  **Biologics** | Mammalian (mAb, BsAb/TsAb), ADC & Fabs, Fusion, Recombinant Proteins
-  **Small Molecule** | OSD Tablets & Capsules

### Global Manufacturing Footprint



#### Hopewell Site Flagship U.S. Biologics Manufacturing Center

- Since 2024
- 42-acre site, 400,000 sq ft built
- Total 8kl cell culture capacity
- Phase II + for small molecule, ADC & other

#### Guangzhou Site Biologics & ADC Manufacturing

- Since 2019
- 39-acre site, 1.3 million sq ft built
- Total 65kl cell culture capacity
- Liquid, lyo, PFS capability
- ADC conjugation up to 500L

#### Suzhou Site Small Molecule Manufacturing

- Since 2017
- 12.4-acre site, 460,000 sq ft built
- Total 600M tablet/capsule capacity

### Hopewell Manufacturing Site

Expansion of State-of-the Art Manufacturing Facility



#### Drug Substance

##### Manufacturing Capabilities

- Total 8kl cell culture capacity
  - Single-use system (4 x 2kl)
  - Batch, fed-batch, and perfusion
- Faster expansion through modular system
- Room reserved for additional 4 x 2kl



#### Drug Products

##### DP Production Lines

- Isolators
- Liquid vials (clinical & commercial)
- Lyophilized vials (clinical & commercial)
- Labeling & packaging



#### QC & MST Labs

##### Lab Capabilities

- Analytical method development, validation, and transfer
- QC testing (release, IPC, stability and more)
- Tech transfer, process validation, MFG tech support



#### Warehouse

##### Equipped with Latest Technology

- ASRS (automatic search & retrieval system)
- Storage conditions: 2 - 8°C, -20°C, -70°C

## Partnering with BeOne

### State-of-the-Art Facilities, Biologics Expertise, Global Scale

- **Accelerate market entry** with high quality and cost efficiency
  - 200 scientists and engineers in process development and CMC
  - End-to-end CMC solutions with proprietary cell line and media
  - mAb, BsAb, TsAb, and ADC
  - Global scalable network that mitigates supply chain & geopolitical risks
  - Track record of scaling up 30+ clinical and commercial assets, 50L tox to 5,000L commercial
- **Strategic partner** with deep experience in developing, producing, distributing globally
- **Flexibility in partnering model** to create win-win outcomes

### Contact Us

info.manufacturing@beonemed.com  
www.beonemed.com



@BeOneMedicines



@BeOneMeds



## Analytical & CMC Capabilities



### QC Lab

#### Global Testing Platform

- Analytical method validation & transfer
- Global stability center & reference standard management center



### PD Lab

#### Large Molecule Development Platform

- Cell line & process development
- Media development, proprietary media
- Formulation development



### CMC

#### End-to-End CMC Strategies & Management

- Fast to IND, BLA strategies
- Internal & external program management

## Molecule to IND and Beyond



- 250mL to 50L
- 500L to 2kL
- Proprietary afucosylated CHO & Media
- Industry-leading productivity: 8-10g/L for mAbs, 5-8g/L for complex molecules
- Media, buffer & excipient screening
- Assay development & characterization study

## Global Quality Systems



30+ Approvals & inspections in 5+ years  
0 critical observations

(US FDA, EMA, China NMPA, ANVISA, TGA, MFDS +)



16 Approved products  
40+ clinical & commercial assets  
45+ phase 3 or potentially registration enabling trials

- **Globalized Quality System** enables the quick and efficient biologics CMC development
- **Phase-Appropriate Strategy** meets international GMP regulatory requirements

## Global Network



40 offices, ~12,000 colleagues across 6 continents  
1,600+ global technical operations team



~20 industry collaborations

\*Numbers as of November 2025